诱骗受体3在上皮性卵巢癌组织中的表达与临床病理特征的相关性研究

Association between expression of decoy receptor 3 in patients with epithelial ovarian cancer and clinical pathology characteristics

目的研究诱骗受体3（DcR3）在人上皮性卵巢癌组织的表达及其临床意义。方法对2012年3月至2015年6月我院妇产科收治并手术治疗的66例上皮性卵巢癌组织及41例良性卵巢肿瘤组织的临床资料及组织病理学标本进行回顾性分析。用免疫组织化学SP法检测良性卵巢肿瘤组织及上皮性卵巢癌组织中DcR3蛋白的表达水平,用已知阳性组织切片作为阳性对照,以PBS溶液代替一抗作为阴性对照,分析其表达与患者临床病理学特征及生存时间的关系。结果在上皮性卵巢癌中,Ⅰ～Ⅱ与Ⅲ～Ⅳ期的DcR3阳性表达率分别为68.4%和89.4%,Ⅲ～Ⅳ期与Ⅰ～Ⅱ期比较差异有统计学意义（P〈0.05）;高、低2个分化组DcR3阳性表达率分别为66.7%和91.1%,低分化组与高分化组比较差异有统计学意义（P〈0.05）;淋巴结转移组的DcR3阳性表达率为91.3%,与无转移组的65.0%比较差异有统计学意义（P〈0.05）。免疫组化染色显示,DcR3主要在细胞质和细胞膜中表达,DcR3在上皮性卵巢癌组织及良性卵巢肿瘤组织中的阳性表达率分别为83.3%,29.3%,癌组织与良性肿瘤组织比较差异有统计学意义（P〈0.05）。DcR3阳性患者的中位生存时间为28.4个月,与阴性患者的50.2个月比较差异有统计学意义（HR=1.90,95%CI：1.09～3.66,P〈0.05）。结论 DcR3蛋白可作为卵巢癌患者的预后不良的生物学标志物。

Objective To evaluate the association between decoy receptor3（ DcR3） expression and clinical pathology characteristics in patients with epithelial ovarian cancer. Methods Sixty- six patiens with epithelial ovarian cancer and 41 cases with benign ovarian tumor were retrospectively analyzed from Mar 2012 to Jun 2015 in our hospital. The cancer tissue and benign ovarian tumor tissue were tested for decoy receptor 3（ DcR3） expression by immunohistochemical method. The known positive sample was used as positive control and the PBS solution was used as negative blank control. The clinical pathology characteristic prognosis with DcR3 expression was evaluated by statistical software. The overall survival was also assessed according to DcR3 positive or negative.Results The clinical pathology analysis showed that the DcR3 positive expression rate were 68. 4% and 89. 4% for Ⅰ- Ⅱ and Ⅲ- Ⅳ stage patients with statistical difference（ P 〈 0. 05）. DcR3 positive expressionrate were 66. 7% and 91. 1% for well differentiation and poor differentiation group respectively with statistical difference（ P 〈 0. 05）. The DcR3 positive expression rate in lymph node metastasis group was much higher than that of non- metastasis group（ 91. 3% vs 65. 0%） with statistical difference（ P 〈 0. 05）. DcR3 was mainly expressed in cytoplasm and cell membrane. The DcR3 positive expression in cancer tissue and benign tumor tissue were 83. 3% and29. 3% respectively which indicated cancer tissue significant higher than that of benign tumor tissue（ P 〈 0. 05）. The median survival for DcR3 positive and negative patients were 28. 4 months and 50. 2 months（ HR = 1. 90,95% CI：1. 09- 3. 66,P 〈 0. 05）. Conclusion DcR3 was highly expressed in cancer tissue and associated with poor prognosis,which could be biomarker for prognosis.